International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
